The Cancer Therapeutics Research Group (CTRG) was formed in October 1997 by Professor John Wong (National University Hospital) and Professor James Bishop (Sydney Cancer Centre) as part of the drive to develop Singapore into a life sciences hub and centre for drug development and clinical trials.
Since then, the Group has expanded to 8 member institutions, which is a testimony of the rising standards of the groupai??i??s research infrastructure in the Asia-Pacific region.
The current member institutions are:
ai??? National University Cancer Institute, Singapore, National University Health System, Singapore
ai??? Johns Hopkins Singapore International Medical Centre, Singapore
ai??? The Chinese University of Hong Kong, Hong Kong SAR, China
ai??? National Cancer Centre, Singapore
ai??? Yonsei Cancer Centre, Seoul, Korea
ai??? Sir Charles Gairdner Hospital, Perth, Australia
ai??? National Taiwan University Hospital, Taipei, Taiwan
ai??? Department of Haematology, Singapore General Hospital, Singapore
The need for high quality and well-coordinated clinical trial groups in Asia-Pacific has provided many opportunities for the CTRG in clinical trials and translational research, having established itself as a leader in this region. The institutions forming the CTRG collectively bring extensive experience in oncology drug development.
CTRG have collaborated with many multinational pharmaceutical and biotechnology companies, as well as research institutions, to conduct clinical trials in cancer and for cancer drug development. Such research collaborations and partnerships have enabled cancer patients in Singapore and the region to benefit greatly with much earlier access to the latest chemotherapy regimens and novel molecular targets for cancer treatment before their availability in the market. These collaborations have brought valuable investments into Singapore thus benefiting the biomedical and pharmaceutical industries here.
CTRG is positioned as a major centre for early phase drug development in clinical trials with more sophisticated endpoints, and with expertise in Phase I and translational research. The Group has Phase 1-2 dedicated facilities/resource. Located in a region of multi-ethnicities, the CTRG also conducts research to understand interethnic variability of anticancer drugs. CTRG also has capability to assay anti-cancer drugs at greater sensitivity and specificity, including metabolite analysis.
CTRG is, undoubtedly, in an exciting phase of development and their efforts are being recognised increasingly by the international academic community and industry.
Going forward, the Group will continue to bring together key opinion leaders in Asia Pacific, attract drug companies to conduct clinical trials, and gain recognition through publications in high impact journals.
- To provide the means and opportunity to test novel anticancer agents and therapeutic strategies simultaneously in Asian & Caucasian patients with cancer
- To study pharmacogenomics in relation to ethnicity
- To develop better therapies for cancers common in Asia-Pacific
- To provide high quality data through ICH-GCP compliant clinical trials for rapid registration and licensing of new compounds in Asia
Our Set Up
- The administrative head office is located in the National University Hospital, Singapore.
- Our Group is led by a Joint Management Committee (JMC), comprising of the Directors of each member institution and a Chairman elected on an annual rotating basis.
- An audit committee audits our clinical trials conducted at the participating member institutions on a regular basis.
- We have established comprehensive Standard Operating Procedures (SOPs) to ensure smooth operations within the Group.
- Business meetings are conducted annually.
- Our Group keeps in close contact and follows discussions closely through regular teleconferences.